NorthWest Biotherapeutics Inc (NWBO)

[sentiment_stocks]

Investors here are always looking to see if mentions of DCVax-L make it into the media or into abstracts. I came across an abstract that came out today in Oncology Times entitled "Highlighting Advances in the treatment of Gliomas" and DCVax-L is covered under the Immunotherapy section.

A different approach utilizes cell-based vaccines an example of which is the DCVax-L, a dendritic cell vaccine also in phase III testing in patients with newly diagnosed glioblastoma. Autologous tumor antigens are obtained at the time of surgery and exposed to dendritic cells also derived from the patient. The “pulsing” of the dendritic cells with tumor cells and their training to recognize tumor cells specific to the patient results in a personalized dendritic vaccine that is then administered back into the patient. The dendritic antigen presenting cells can activate a tumor specific CD4 and CD8 T-cell response that can potentially target the patient's tumor in a highly-specific manner (Hum Vaccin Immunother 2014;10(11):3139-3145). The placebo-controlled phase III trial testing the vaccine with standard-of-care therapy in newly-diagnosed glioblastoma had enrolled 331 of the projected 348 patients as of December 2016 and final data analysis and results are currently pending as survival data matures.

http://journals.lww.com/oncology-times/Fulltext/2017/08100/Highlighting_Advances_in_the_Treatment_of_Gliomas.2.aspx

If you'll notice that when they point out at the end that results are pending as the survival data matures, they aren't questioning the logic of letting the survival data mature. They refer to it in a matter-of-fact, this is a normal thing, kind of fashion.

The authors are with Ohio State University, which is a trial site for L, but neither of them are actual investigators with the trial.